Malaria remains a global health threat, with Plasmodium falciparum causing most deaths, especially in sub-Saharan Africa. Although artemisinin-based therapies reduce the burden, drug-resistant parasites threaten control efforts. Mapping the distribution and evolution of molecular resistance markers is vital for evidence-based strategies. This systematic review mapped the global distribution, pooled prevalence, and temporal trends of key P. falciparum antimalarial resistance markers. Following the PRISMA methodology (PROSPERO: CRD4202511098991), databases (PubMed, Web of Science, Scopus, and Google Scholar) and gray sources were searched (July 2005–July 2025). Data were extracted in Rayyan, assessed via the JBI prevalence tool, and analyzed using Python v3.13 for WHO regional distribution, temporal trends, and treatment outcome trends. Of the 1972 records, 261 studies from 64 countries qualified for inclusion in this review. The pooled prevalence was highest for pfdhfr (85.7%), followed by pfcrt (78.0%), pfdhps (73.7%), pfmdr1 (60.5%), and pfk13 (45.0%). High heterogeneity (I2 > 95%) and rising pfk13 since 2012 highlight emerging artemisinin resistance, while persistent pfdhfr/pfdhps mutations show that ongoing sulfadoxine–pyrimethamine (SP) pressure on P. falciparum drug resistance, decreased parasite clearance, and treatment failure remain widespread and evolving in Africa. Integrating molecular surveillance into national malaria programs is essential to guide treatment modalities and support progress toward malaria elimination.
Breast cancer (BC) remains a leading cause of cancer-related morbidity and mortality worldwide, with substantial disparities in incidence, subtype distribution, and outcomes across different populations and settings. In Rwanda, evidence regarding the molecular subtypes of BC and their associations with sociodemographic, clinical and pathological characteristics remains limited. We conducted a retrospective cohort study of women with histologically confirmed BC between January 2014 and June 2021 across four major referral hospitals in Rwanda. Data on sociodemographic, clinical, and pathological characteristics—including ER, PR, and HER2 immunohistochemical status—were extracted from medical records. Tumors were categorized into Luminal A/B (ER + and/or PR+), HER2-enriched (ER-/PR-/HER2+), and triple-negative breast cancer (TNBC; ER-/PR-/HER2-). Associations between subtype and key features were assessed using chi-square and Fisher’s Exact tests and multinomial logistic regression. Survival analysis was performed using the Kaplan-Meier method. The mean age (± SD) among women (N = 889) included in this analysis was 50.9 (± 12.9). The most common molecular subtype was luminal A/B (67
Introduction : La vessie neurogène psychogène est une affection rare caractérisée par des troubles mictionnels sans lésion organique identifiable. La prise en charge psychologique est essentielle. Observation : Nous rapportons le cas d’une patiente de 28 ans, sans antécédents urologiques, présentant des mictions impérieuses et des fuites urinaires depuis 2 ans. L’examen urologique était normal. Résultats : L’évaluation psychologique a révélé un contexte de stress professionnel majeur et des conflits familiaux non résolus. Une psychothérapie de soutien associée à des techniques de relaxation a permis une amélioration significative des symptômes. Conclusion : La vessie neurogène psychogène nécessite une prise en charge pluridisciplinaire intégrant le psychologue dans le parcours de soins. Mots-clés : vessie neurogène psychogène, prise en charge psychologique, psychothérapie.
Genomic surveillance has become an indispensable tool for the identification of pathogens and tracking of transmission chains. Building upon the global sequencing and surveillance infrastructure developed and expanded during the COVID-19 pandemic, these capacities are now being adapted to track other pathogens in low- and middle-income countries which remain disproportionately affected by infectious diseases. This is evident in the recent and unprecedented spread of mpox virus in regions experiencing multiple concurrent infectious disease outbreaks, highlighting the need for broad, adaptable diagnostic detection and sequencing capacity. In this Perspective, we describe the applications, insights, and challenges encountered during ongoing capacity building efforts for the characterization of the mpox outbreak and other emerging pathogens in the African Great Lakes Region.